Gentex price target lowered to $27 from $30 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Gentex (GNTX) to $27 from $30 and keeps a Neutral rating on the shares. While there were elements of Gentex’s Q3 report that were positive, the challenges to the core business are likely to be an incremental concern heading into 2026, the analyst tells investors in a research note. Gentex’s business should benefit from product cycles, but it is also facing headwinds in China due to tariffs and in Europe, Goldman adds.